# A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

> **NCT03345836** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 624 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Matching Placebo for Upadacitinib
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT03345836
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2021-08-11
- **Final completion:** 2021-08-11
- **Target enrollment:** 624 (ACTUAL)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345836, "A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03345836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*